HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

[Pulmonary toxicity by pegylated interferon alpha-2a in a patient with chronic hepatitis C].

Abstract
The combination therapy with pegylated interferon alpha and ribavirin has increasingly prescribed for chronic hepatitis C. Although many side effects of interferon such as flu-like symptoms, gastrointestinal and neuropsychiatric symptoms are well known, only several cases of interferon-induced pulmonary toxicity have been reported. Interferon-induced pulmonary toxicity usually develops from 2 weeks to 12 weeks after treatment for HCV infection. Diagnosis is commonly based on clinical findings such as a dry cough, dyspnea, hypoxemia, and a restrictive pattern in pulmonary function testing, bilateral diffuse parenchymal infiltrations, histopathological findings of interstitial pneumonitis, and exclusion of any other causative agents. Prompt withdrawal of the drug is the cornerstone of treatment. We report a case of PEG-IFN alpha-2a induced pulmonary toxicity in a 50-year-old male patient with hepatitis C. To our knowledge, this is the first case of pegylated interferon alpha-2a induced pulmonary toxicity in Korea.
AuthorsByoung Kwan Son, Joo Hyun Sohn, Tae Yeob Kim, Yoon Kyung Park, Yong Chul Jeon, Dong Soo Han
JournalThe Korean journal of hepatology (Korean J Hepatol) Vol. 13 Issue 1 Pg. 103-7 (Mar 2007) ISSN: 1738-222X [Print] Korea (South)
PMID17380081 (Publication Type: Case Reports, Journal Article)
Chemical References
  • Antiviral Agents
  • Interferon alpha-2
  • Interferon-alpha
  • Recombinant Proteins
  • Polyethylene Glycols
  • Ribavirin
  • peginterferon alfa-2a
Topics
  • Antiviral Agents (administration & dosage, adverse effects, therapeutic use)
  • Hepatitis C, Chronic (drug therapy)
  • Humans
  • Interferon alpha-2
  • Interferon-alpha (administration & dosage, adverse effects, therapeutic use)
  • Lung Diseases (chemically induced, diagnosis, pathology)
  • Male
  • Middle Aged
  • Polyethylene Glycols (administration & dosage, adverse effects, therapeutic use)
  • Recombinant Proteins
  • Ribavirin (administration & dosage, therapeutic use)
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: